CD8A and myeloid sarcoma: In contrast to anti-CD20-treated MS patients, mRNA vaccination of SARS-CoV-2 naïve MTX-treated patients with immune-mediated inflammatory disease (IMID) did not induce activated CD8+ T cells following mRNA vaccination (Haberman et al., 2020).